Preliminary report of a clinical trial supporting the sequential use of an attenuated E39 peptide (E39') to optimize the immunologic response to the FBP (E39+GM-CSF) vaccine

Detalles Bibliográficos
Autores principales: Jackson, Doreen, Qiao, Na, Greene, Julia M, Hale, Diane, Berry, John, Trappey, Alfred, Vreeland, Timothy, Clifton, Guy, Ibrahim, Nuhad, Toms, Annie, Peoples, George E, Mittendorf, Elizabeth A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Poster Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645458/
http://dx.doi.org/10.1186/2051-1426-3-S2-P156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645458/
http://dx.doi.org/10.1186/2051-1426-3-S2-P156

Ejemplares similares